BioArctic Stock

BioArctic EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of BioArctic (BIOA B.ST) as of Aug 6, 2026 is 48.88 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -19.98 % — a change of -344.63% (higher).

EBIT/Assets

48.88 %

YoY

-344.63%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of BioArctic is 2026 48.88 % . Operating Income to Assets Ratio (EBIT/Assets) of BioArctic was 2025 -19.98 % . It decreases by -344.63% higher compared to the previous year.
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Operating Income to Assets Ratio (EBIT/Assets) of BioArctic is 48.88 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of BioArctic changed from -19.98 % to 48.88 %, representing a -344.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — BioArctic

All Key Metrics — BioArctic